BACKGROUND: Apolipoprotein E has previously been demonstrated to modulate acute brain injury responses, and administration of COG1410, an apoE-mimetic peptide derived from the receptor-binding region of apoE, improves outcome in preclinical models of acute neurological injury. In the current study, we sought to establish the optimal dose and timing of peptide administration associated with improved functional outcome in a murine model of intracerebral hemorrhage (ICH). METHODS: Ten to twelve-week-old C57/BL6 male mice were injured by collagenase-induced ICH and randomly selected to receive either vehicle or one of four doses of COG1410 (0.5, 1, 2, or 4 mg/kg) via tail vein injection at 30 min after injury and then daily for 5 days. The injured mice were euthanized at various time points to assess inflammatory mediators, cerebral edema, and hematoma volume. Over the first 5 days following injury, vestibulomotor function was tested via Rotorod (RR) latency. After an optimal dose was demonstrated, a final cohort of animals was injured with ICH and randomly assigned to receive the first dose of COG1410 or vehicle at increasingly longer treatment initiation times after injury. The mice were then assessed for functional deficit via RR testing over the first 5 days following injury. RESULTS: The mice receiving 2 mg/kg of COG1410 after injury demonstrated reduced functional deficit, decreased brain concentrations of inflammatory proteins, and less cerebral edema, although hematoma volume did not vary. The improved RR performance was maintained when peptide administration was delayed for up to 2 h after ICH. CONCLUSIONS: COG1410 administered at a dose of 2 mg/kg within 2 h after injury improves functional recovery in a murine model of ICH.
BACKGROUND:Apolipoprotein E has previously been demonstrated to modulate acute brain injury responses, and administration of COG1410, an apoE-mimetic peptide derived from the receptor-binding region of apoE, improves outcome in preclinical models of acute neurological injury. In the current study, we sought to establish the optimal dose and timing of peptide administration associated with improved functional outcome in a murine model of intracerebral hemorrhage (ICH). METHODS: Ten to twelve-week-old C57/BL6 male mice were injured by collagenase-induced ICH and randomly selected to receive either vehicle or one of four doses of COG1410 (0.5, 1, 2, or 4 mg/kg) via tail vein injection at 30 min after injury and then daily for 5 days. The injured mice were euthanized at various time points to assess inflammatory mediators, cerebral edema, and hematoma volume. Over the first 5 days following injury, vestibulomotor function was tested via Rotorod (RR) latency. After an optimal dose was demonstrated, a final cohort of animals was injured with ICH and randomly assigned to receive the first dose of COG1410 or vehicle at increasingly longer treatment initiation times after injury. The mice were then assessed for functional deficit via RR testing over the first 5 days following injury. RESULTS: The mice receiving 2 mg/kg of COG1410 after injury demonstrated reduced functional deficit, decreased brain concentrations of inflammatory proteins, and less cerebral edema, although hematoma volume did not vary. The improved RR performance was maintained when peptide administration was delayed for up to 2 h after ICH. CONCLUSIONS: COG1410 administered at a dose of 2 mg/kg within 2 h after injury improves functional recovery in a murine model of ICH.
Authors: H N Dawson; V Cantillana; M Jansen; H Wang; M P Vitek; D M Wilcock; J R Lynch; D T Laskowitz Journal: Neuroscience Date: 2010-04-29 Impact factor: 3.590
Authors: Feng-Qiao Li; Gregory D Sempowski; Suzanne E McKenna; Daniel T Laskowitz; Carol A Colton; Michael P Vitek Journal: J Pharmacol Exp Ther Date: 2006-06-01 Impact factor: 4.030
Authors: John R Lynch; Haichen Wang; Brian Mace; Stephen Leinenweber; David S Warner; Ellen R Bennett; Michael P Vitek; Suzanne McKenna; Daniel T Laskowitz Journal: Exp Neurol Date: 2005-03 Impact factor: 5.330
Authors: John R Lynch; Wen Tang; Haichen Wang; Michael P Vitek; Ellen R Bennett; Patrick M Sullivan; David S Warner; Daniel T Laskowitz Journal: J Biol Chem Date: 2003-09-24 Impact factor: 5.157
Authors: Beilei Lei; Huaxin Sheng; Haichen Wang; Christopher D Lascola; David S Warner; Daniel T Laskowitz; Michael L James Journal: J Vis Exp Date: 2014-07-03 Impact factor: 1.355
Authors: Jeffrey T Guptill; Shruti M Raja; Felix Boakye-Agyeman; Robert Noveck; Sarah Ramey; Tian Ming Tu; Daniel T Laskowitz Journal: J Clin Pharmacol Date: 2016-12-19 Impact factor: 3.126
Authors: Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu Journal: Acta Neuropathol Date: 2016-02-16 Impact factor: 17.088
Authors: Beilei Lei; Brian Mace; Steven T Bellows; Patrick M Sullivan; Michael P Vitek; Daniel T Laskowitz; Michael L James Journal: Transl Stroke Res Date: 2012-03 Impact factor: 6.829
Authors: Kathryn N Kearns; Natasha Ironside; Min S Park; Bradford B Worrall; Andrew M Southerland; Ching-Jen Chen; Dale Ding Journal: Neurocrit Care Date: 2021-08-02 Impact factor: 3.210